Search

Josh Wallsh,1 Charlotte Luths,2 Haily Kil,2 Ron Gallemore2 1Albany Medical Center, Department of Ophthalmology, Albany, NY, USA; 2Retina Macula Institute and Research Center, Torrance, CA, USACorrespondence: Ron GallemoreRetina Macula Institute and Research Center, 4201 Torrance Blvd Suite 220, Torrance, CA 90503, USAEmail rongallemoremd@gmail.comPurpose: To evaluate the initial ten years of results from the intravitreal dexamethasone implant (DEX) in patients treated for retinal vein occlusion (RVO), diabetic macular edema (DME) or uveitis.Methods: Retrospective chart review of patients receiving DEX since its FDA approval. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure and cataract status were collected. Baseline data were collected from the initial DEX and post-treatment data at the visit at least four weeks after the last DEX.Results: In total, 315 eyes received 1216 DEX over 63.9± 4.6 weeks. In the branch RVO (n=90), central RVO (n=59) and DME (n=62) cohorts, BCVA improved significantly (p< 0.05). The uveitis (n=154) cohort did not have a significant change in BCVA, 0.62± 0.04 to 0.61± 0.04 logMAR (p=0.34). Younger patients, vitrectomized eyes, and eyes without a history of glaucoma were associated with significantly better BCVA outcomes in the uveitis cohort (p< 0.05). Overall, CMT decreased significantly from 376.6± 6.8 to 322.7± 5.0 μm (p< 0.05). Intraocular pressure increased significantly (p< 0.001) and the percentage of patients requiring anti-glaucoma medications increased from 33.0% to 67.6%. Of phakic eyes, 58.8% (n=63) had cataract progression or underwent surgery with those who underwent surgery experiencing a significant improvement in BCVA (p< 0.05).Conclusion: Repeated DEX over extended follow-up offers significant anatomic benefits to all cohorts. Visual benefits are only seen in RVO, DME and select uveitis demographics.Keywords: uveitis, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, dexamethasone implant

Jea H Yu,1 Jaycob Avaylon,1 Hyein Kil,1 Jisoo K Kim,1 Ron P Gallemore1,21Department of Clinical Research, Retina Macula Institute, Torrance, CA, USA; 2Department of Ophthalmology, University of California, Los Angeles, CA, USAPurpose: To report a case of endophthalmitis associated with Legionella Pneumophila.Case Report: A 46-year-old, highly myopic male with a complex history of recurrent retinal detachments, macular hole, cataract surgery and an infected scleral buckle in the left eye, presented with pain, redness, hypopyon and vision loss in the left eye, 14 days following blunt head trauma. Empirical treatment for endophthalmitis with intravitreal injections of Vancomycin and Ceftazidime afforded minimal improvement. He developed recurrent hypopyon and underwent vitrectomy surgery with intravitreal antibiotic injections at the time of surgery and had improvement. Intraoperative culture was positive for Legionella Pneumophila. He had continued episodes of recurrent inflammation which were quelled by intravitreal moxifloxacin injections performed every 3–10 days. He developed a recurrent RD with proliferative vitreoretinopathy (PVR) and underwent vitrectomy with silicone oil. The retina was reattached but had no light perception vision in the affected eye.Conclusion: When endophthalmitis is contracted in a work-place setting, a culture for L. pneumophila should be considered. A combination of intravitreal moxifloxacin and oral azithromycin may be effective.Keywords: endophthalmitis, Legionella Pneumophila, Legionnaire’s disease